WO2013071459A3 - Composition comprenant un glucocorticoïde et une tiazolinédione pour induire une différenciation adipogène complète des cellules mères de mammifères - Google Patents

Composition comprenant un glucocorticoïde et une tiazolinédione pour induire une différenciation adipogène complète des cellules mères de mammifères Download PDF

Info

Publication number
WO2013071459A3
WO2013071459A3 PCT/CL2012/000076 CL2012000076W WO2013071459A3 WO 2013071459 A3 WO2013071459 A3 WO 2013071459A3 CL 2012000076 W CL2012000076 W CL 2012000076W WO 2013071459 A3 WO2013071459 A3 WO 2013071459A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
thiazolinedione
glucocorticoid
composition
adipogenic differentiation
Prior art date
Application number
PCT/CL2012/000076
Other languages
English (en)
Spanish (es)
Other versions
WO2013071459A2 (fr
Inventor
Paulette CONGET MOLINA
David CONTADOR MARTINEZ
Original Assignee
Universidad Del Desarrollo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Del Desarrollo filed Critical Universidad Del Desarrollo
Priority to US14/354,040 priority Critical patent/US20140315870A1/en
Publication of WO2013071459A2 publication Critical patent/WO2013071459A2/fr
Publication of WO2013071459A3 publication Critical patent/WO2013071459A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition qui comprend un glucocorticoïde et une tiazolinédione pour induire une différenciation adipogène, qui permet de générer des cellules matures fonctionnelles, à partir de cellules mères indifférenciées humaines ou d'autres mammifères, embryonnaires ou adultes, idéalement des cellules mères mésenchymateuses humaines. Le glucocorticoïde préféré correspond à une dexaméthasone et la tiazolinédione préférée à une rosiglitazone. Bien entendu, l'invention s'étend aux familles des deux composés.
PCT/CL2012/000076 2011-10-24 2012-12-24 Composition comprenant un glucocorticoïde et une tiazolinédione pour induire une différenciation adipogène complète des cellules mères de mammifères WO2013071459A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/354,040 US20140315870A1 (en) 2011-10-24 2012-12-24 Composition comprising a glucocorticoid and a thiazolidinedione for inducing compelte adipogenic differentiation of mammalian stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL26422011 2011-10-24
CL2642-2011 2011-10-24

Publications (2)

Publication Number Publication Date
WO2013071459A2 WO2013071459A2 (fr) 2013-05-23
WO2013071459A3 true WO2013071459A3 (fr) 2013-09-06

Family

ID=48430272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CL2012/000076 WO2013071459A2 (fr) 2011-10-24 2012-12-24 Composition comprenant un glucocorticoïde et une tiazolinédione pour induire une différenciation adipogène complète des cellules mères de mammifères

Country Status (1)

Country Link
WO (1) WO2013071459A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008893A1 (en) * 2007-12-28 2011-01-13 Fujirebio Inc. Medium for mammalian somatic cells and additive therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008893A1 (en) * 2007-12-28 2011-01-13 Fujirebio Inc. Medium for mammalian somatic cells and additive therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALVORSEN Y D ET AL.: "Thiazolidinediones and glucocorticoids synergistically induce differentiation of human adipose tissue stromal cells: biochemical, cellular, and molecular analysis.", METABOLISM, CLINICAL AND EXPERIMENTAL., vol. 50, no. 4, April 2001 (2001-04-01), pages 407 - 413 *
RYDEN M ET AL.: "Functional characterization of human mesenchymal stem cell-derived adipocytes.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 311, no. 2, 14 November 2003 (2003-11-14), pages 391 - 397 *
TCHOUKALOVA Y D ET AL.: "Enhancing effect of troglitazone on porcine adipocyte differentiation in primary culture: a comparison with dexamethasone.", OBESITY RESEARCH., vol. 8, no. 9, 2000, pages 664 - 672 *

Also Published As

Publication number Publication date
WO2013071459A2 (fr) 2013-05-23

Similar Documents

Publication Publication Date Title
EP4292600A3 (fr) Photorécepteurs et progéniteurs de photorécepteurs produits à partir de cellules souches pluripotentes
WO2011021194A3 (fr) Cellules progénitrices de péricyte et leurs procédés de génération et d'utilisation
HK1217110A1 (zh) 在空氣-液體界面處培養人胚胎幹細胞以用於分化成胰腺內分泌細胞
WO2012107778A3 (fr) Pores mutants
CO7170149A2 (es) Producción mejorada de derivados de ácidos grasos
PH12015501477A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
TR201909777T4 (tr) Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
GEP20176628B (en) Targeted genomic alteration
NZ609660A (en) Methods of isolating non-senescent cardiac stem cells and uses thereof
ECSP14013339A (es) Compuestos con actividad nematicida
WO2012166997A3 (fr) Réacteur électrochimique et procédé associé
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
WO2013033626A3 (fr) Produits thérapeutiques ciblant un récepteur nkp30
WO2014100779A8 (fr) Procédés de production de plaquettes à partir de cellules souches pluripotentes, et compositions associées
IN2014DN06740A (fr)
SG179561A1 (en) Composition and method for imaging stem cells
EP3234109A4 (fr) Culture en suspension de cellules souches pluripotentes
MY182924A (en) Enzyme compositions and uses thereof
WO2011100286A3 (fr) Compositions et méthodes de production d'une cellule mésodermique différenciée
GB2536366A (en) Mammalian muscle-derived stem cells
EP2539440A4 (fr) Dérivation de cellules hématopoïétiques à partir de cellules souches mesenchymateuses adultes
CA2843611C (fr) Compositions et methodes pour reduire l'incidence de troubles digestifs chez des equides
IN2014CN02963A (fr)
WO2012058637A3 (fr) Dosages d'antisérums pour virus apparentés au mlv chez des êtres humains et d'autres mammifères
WO2012173358A3 (fr) Cellules souches pluripotentes issues de cellules somatiques du testicule, procédé de production de celles-ci, et composition pharmaceutique pour le traitement de l'impuissance comprenant celles-ci

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 14354040

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12849602

Country of ref document: EP

Kind code of ref document: A2